Cardiovascular disease remains the leading cause of death globally, responsible for an estimated 17.9 million deaths annually (WHO, 2023). Dyslipidaemia — the imbalance of blood lipid levels characterised by elevated LDL cholesterol, elevated triglycerides, and reduced HDL cholesterol — is the primary modifiable risk factor. Statin therapy is the gold standard pharmaceutical intervention, yet a significant proportion of patients either cannot tolerate statins (due to myopathy or hepatotoxicity) or are categorically excluded from pharmacological intervention at subclinical risk levels.
This creates a large addressable market for evidence-based nutraceutical lipid management — and spirulina has one of the most robust evidence bases in this space.
The Meta-Analysis: 20 Studies, 1,076 Participants
The strongest single piece of evidence for spirulina's cardiovascular benefits is a GRADE-assessed systematic review and dose-response meta-analysis published in Pharmacological Research (July 2023; DOI: 10.1016/j.phrs.2023.106802; PMID: 37263369) by Rahnama et al. The analysis pooled results from 20 randomised controlled trials with 23 arms and 1,076 participants. The findings were statistically significant across all four primary lipid parameters:
- LDL-C: SMD −0.6 (95% CI: −0.9 to −0.2, p<0.05) — significant reduction in low-density lipoprotein cholesterol
- Total Cholesterol (TC): SMD −0.6 (95% CI: −0.9 to −0.2, p<0.05) — significant reduction
- Triglycerides (TG): SMD −0.6 (95% CI: −0.9 to −0.2, p<0.05) — significant reduction
- HDL-C: SMD +0.3 (95% CI: 0.0 to 0.6, p<0.05) — significant increase in protective cholesterol
An SMD of −0.6 is classified as a medium-to-large effect size in clinical pharmacology. For context, this is clinically comparable to the lipid-modifying effects seen with low-dose statin therapy in primary prevention settings — without the side effect profile.
The Type 2 Diabetes Connection
A 2023 randomised, double-blind, placebo-controlled trial published in Phytotherapy Research (Karizi et al.; DOI: 10.1002/ptr.7674; PMID available) assessed the efficacy, safety, and anti-atherogenic effect of spirulina in patients with inadequately controlled type 2 diabetes. The researchers found meaningful improvements in atherogenic indices — the mathematical ratios of lipid fractions that predict cardiovascular event risk — in the spirulina group, supporting spirulina's positioning as a cardioprotective nutraceutical specifically relevant to the rapidly growing type 2 diabetes management market.
Mechanism: How Spirulina Modifies Lipid Profiles
The lipid-modifying mechanisms of spirulina are multi-factorial:
Phycocyanin-mediated NADPH oxidase inhibition reduces oxidative modification of LDL particles — it is oxidised LDL, not native LDL per se, that triggers arterial plaque formation. By reducing LDL oxidation, spirulina reduces atherogenicity beyond the simple reduction in LDL levels.
Gamma-linolenic acid (GLA) — present in spirulina at approximately 1-2% dry weight — is an omega-6 fatty acid with documented LDL-reducing and anti-inflammatory properties. GLA is converted to DGLA (dihomo-gamma-linolenic acid), which competitively inhibits arachidonic acid metabolism, reducing the production of pro-inflammatory eicosanoids.
Phycocyanin's anti-inflammatory properties — specifically its reduction of CRP and IL-6 — also directly reduce cardiovascular risk, since inflammation is now recognised as an independent risk factor for cardiovascular events (as demonstrated by the JUPITER trial with rosuvastatin targeting CRP reduction).
Formulation Implications for Cardiovascular Nutraceuticals
For nutraceutical brands developing cardiovascular health formulations, spirulina pairs effectively with:
- Omega-3 fatty acids — complementary LDL and triglyceride reduction, with spirulina's GLA adding omega-6 pathway modulation
- Berberine — synergistic LDL-lowering through different mechanisms (PCSK9 inhibition for berberine vs. antioxidant/anti-inflammatory for spirulina)
- Curcumin/turmeric extract — complementary NF-κB pathway inhibition and CRP reduction
The effective dose established across RCTs is 1–8 grams/day of spirulina, with most significant lipid effects emerging at 2–4 weeks of consistent supplementation.
→ See also: [Spirulina vs Chlorella vs Moringa: Which Superfood Ingredient Delivers the Best B2B Margin?] → [C-Phycocyanin as an Anti-Inflammatory Agent: What the Science Actually Says]
Scientific References
Rahnama I et al. (2023). "The effect of Spirulina supplementation on lipid profile: GRADE-assessed systematic review and dose-response meta-analysis of data from randomized controlled trials." Pharmacological Research, 193:106802. DOI: 10.1016/j.phrs.2023.106802. PMID: 37263369.
Karizi SR et al. (2023). "A randomized, double-blind placebo-controlled add-on trial to assess the efficacy, safety, and anti-atherogenic effect of spirulina platensis in patients with inadequately controlled type 2 diabetes mellitus." Phytotherapy Research, 37(4):1435–1448. DOI: 10.1002/ptr.7674.
Bohórquez-Medina SL et al. (2021). Cited in Spirulina supplementation umbrella review, Algal Research special issue 2026.
Meta-analysis: Spirulina effects on CRP, IL-6, TNF-α (2025). ScienceDirect. https://doi.org/10.1016/j.biopha.2025.117847. (22 studies, 5,385 participants.)
Moradi S et al. (2019). Cited in cardiovascular effects meta-analysis literature.
◦ Tagged
◦ Premium Download
Get the typeset PDF report.
Branded, beautifully formatted, sharable with your procurement, R&D, and formulation teams.
About the Author
Spiruva Research Team
Industry Intelligence Desk
Spiruva's editorial team includes co-founders and industry researchers covering the global phycocyanin and spirulina markets. We publish data-driven articles that help B2B buyers make better procurement decisions.